Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs
Hims & Hers partnered with Eli Lilly to offer Lilly's FDA-approved weight loss drugs, Zepbound and Foundayo, through its platform. Patients can receive prescriptions and have medications shipped directly. Shares of Hims & Hers rose 8% on the news. The deal follows a similar agreement with Novo Nordisk and reflects Hims & Hers' shift to branded drugs from compounded versions.
How this was made
The 30-second read
Why it matters
The deal provides Hims & Hers with direct access to high‑demand branded obesity drugs, driving an immediate share price jump. For Lilly, the agreement adds a new distribution channel but is unlikely to materially shift its earnings outlook.
Market read
The partnership is a catalyst for HIMS, prompting short‑term buying pressure, while offering Lilly modest distribution benefits.
What to watch
Potential regulatory scrutiny of telehealth drug sales and competition from other digital health platforms.
Background
Hims & Hers (HIMS) is a telehealth company expanding its obesity‑treatment portfolio. Eli Lilly (LLY) is a major pharma firm with FDA‑approved GLP‑1 drugs Zepbound and Foundayo.
Ticker impact
Shares of Hims & Hers rose about 8% on Friday after the company announced a partnership with Eli Lilly to sell branded GLP‑1 obesity drugs.
likely upward pressure as the market prices in higher revenue potential from the Lilly deal
The deal expands Hims & Hers' product offering and immediately moved the stock 8% higher, indicating trader interest.
Eli Lilly entered a distribution agreement with Hims & Hers to sell its GLP‑1 obesity drugs directly through the telehealth platform.
limited upside as the partnership adds a new sales channel but does not change Lilly's core business
Lilly's revenue impact is incremental; the market reaction is focused on Hims & Hers.
Market effects
Strengthens the telehealth/online health sector and highlights growing demand for GLP‑1 obesity treatments.
U.S. market focus; no immediate regional spillover.
Shows pharma companies leveraging digital health platforms, a trend of global relevance.
Counterpoint
The partnership may dilute Hims & Hers margins due to lower‑margin branded drugs, potentially limiting upside.
Key entities
- CompanyHims & Hers Health Inc.
Telehealth platform expanding into branded obesity drug sales.
- CompanyEli Lilly and Company
Pharmaceutical manufacturer of GLP‑1 obesity treatments.
